Actively Recruiting
Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Led by Tanta University · Updated on 2026-05-04
46
Participants Needed
1
Research Sites
111 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries. NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. Lifestyle interventions, including dietary modification and exercise, remain the cornerstone of NAFLD treatment. Pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.
CONDITIONS
Official Title
Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult male or female patients older than 18 years
- Diagnosis of fatty liver confirmed by upper abdominal ultrasound
You will not qualify if you...
- Pregnant or breastfeeding women
- Excessive alcohol use (more than 30 g/day for men, more than 20 g/day for women)
- Other chronic liver diseases such as viral hepatitis, drug-induced hepatitis, or autoimmune hepatitis
- Chronic kidney disease
- Hyperparathyroidism or hypoparathyroidism
- Allergy or hypersensitivity to carbocisteine
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tanta Unuversity
Tanta, Egypt, 31527
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here